oter

Monoclonal gammopathies require careful monitoring from "summary" of Hematology Board Review by Francis P. Worden, MD,Rami N. Khoriaty, MD,Kathleen A. Cooney, MD,Michael W. Deininger, MD, PhD

Patients with monoclonal gammopathies, such as multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS), must be closely monitored over time. This is because these conditions can progress and cause serious complications if not managed appropriately. Regular monitoring allows healthcare providers to track the progression of the disease and adjust treatment plans accordingly. One of the key reasons for careful monitoring is to assess the level of monoclonal protein in the blood. This protein, also known as M protein, is produced by abnormal plasma cells and can be detected through blood tests. Monitoring the level of M protein is crucial for determining the response to treatment and detecting any relapse or disease progression. In addition to monitoring M protein levels, healthcare providers also need to keep a close eye on other markers of disease activity, such as beta-2 microglobulin, lactate dehydrogenase, and albumin levels. These markers can provide valuable information about the overall health of the patient and the aggressiveness of the disease. Imaging studies, such as skeletal surveys, MRI, and PET scans, are also important tools for monitoring patients with monoclonal gammopathies. These tests can help identify bone lesions, fractures, or other complications that may arise as a result of the disease. Regular imaging studies allow healthcare providers to intervene early and prevent further damage. In summary, careful monitoring of patients with monoclonal gammopathies is essential for assessing disease progression, determining treatment response, and preventing complications. Regular blood tests, monitoring of disease markers, and imaging studies are all critical components of the monitoring process. By closely monitoring patients over time, healthcare providers can ensure optimal outcomes and quality of life for individuals with these conditions.
    oter

    Hematology Board Review

    Francis P. Worden, MD

    Open in app
    Now you can listen to your microbooks on-the-go. Download the Oter App on your mobile device and continue making progress towards your goals, no matter where you are.